Gilead Sciences (GILD)

AI-powered earnings call analysis for Gilead Sciences. Get insights from quarterly earnings reports with our AI-generated podcast. Educational content only - not investment advice.

15 episodes 5 languages

Next Episode

Gilead Sciences earnings call scheduled for Oct 29, 2026 (after market close)

New episode expected Oct 30, 2026

Latest Episode

Q2 2026 Earnings

6:26 • 8/12/2026

Gilead Sciences (GILD) - Q2 2026

0:00

6:26

Speed:

Q2 2026 Earnings

8:51 • 2026/8/12

Gilead Sciences (GILD) - Q2 2026

0:00

8:51

Speed:

Q2 2026 Earnings

8:29 • 12/08/2026

Gilead Sciences (GILD) - Q2 2026

0:00

8:29

Speed:

Q2 2026 Earnings

9:24 • 12/8/2026

Gilead Sciences (GILD) - Q2 2026

0:00

9:24

Speed:

Q2 2026 Earnings

7:38 • 12.8.2026

Gilead Sciences (GILD) - Q2 2026

0:00

7:38

Speed:

All Episodes

EN - English (3) CN - 中文 (3) FR - Français (3) ES - Español (3) DE - Deutsch (3)

Q2 2026 Earnings

6:26

Gilead delivered 10% base business growth in Q2 2026 driven by HIV, Trodelvy, and Livdelzi, raising full-year HIV guidance to 9-10% and planning two additional launches before year-end.

Q1 2026 Earnings

8:09

Gilead delivered Q1 2026 product sales of $6.9B (+5% YoY) with HIV growth of 10% and Yes2Go blockbuster trajectory, raising full-year guidance $400M while closing transformational acquisitions in oncology and cell therapy.